Could an HIV drug boost cervical cancer treatment?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * ECOG 0 to 2 * FIGO 2018 Stage IIIA (TNM stage T3a N0 M0) FIGO 2018 Stage IIIB (TNM stage T3b N0 M0) FIGO 2018 Stage IIIC (TNM stage Any T N1 M0) * No previous irradiation to the pelvis or chemotherapy * Age 18 years and above * Ability to tolerate full course of pelvic radiotherapy and brachytherapy * Adequate bone marrow, liver, and kidney function defined as neutrophil count ≥ 1500 platelet count ≥ 100,000, total bilirubin less than 1.5 x upper limit of normal (ULN), AST and ALT ≤ 2.5 x ULN, and creatinine less than 1.5 upper limit of normal or Creatinine clearance greater than 60 mL/min/1.73 m2 * No recent (less than 3 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction) * Ability to understand and the willingness to sign an informed consent document * Should be willing to undergo extra biopsy and blood collection for pharmacokinetic studies Exclusion criteria * Patients with newly diagnosed diabetes , uncontrolled DM (patient with HbA1c of \> 6.5% or FBS value or BSF\>=126 mg/dL respectively on primary evaluation) * Pts on any drugs which has pharmacological interaction with nelfinavir: * Terfenadine, cisapride, sildenafil, lovastatin or simvastatin and medication that are metabolized by the CYP3A4 isoenzyme. * Antiarrhythmics (amiodarone, quinidine). * Neuroleptics (pimozide). * Sedative/Hypnotic agents (midazolam, triazolam). * Ergot derivatives. * HMG-CoA reductase inhibitors (atorvastatin). * Rifampicin, Rifabutin. * Felodipine, Nifedipine. * Pregnant or lactating * Active co existing malignancy. * HIV positive patients will be excluded. * Patients with hemophilia. * Patients with reduced creatinine clearance ( less than 50 ml/ min) or unilateral or bilateral hydronephrosis will be excluded. * History of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.